Orthofix Medical Inc.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
CASE ALLEGATIONS: Orthofix is a company specializing in spine and orthopedics, operating both in the United States and internationally.
The Orthofix class action lawsuit claims that during the Class Period, Orthofix and its affiliates made false or misleading statements and/or failed to disclose that Orthofix falsely assured investors that its management team adhered to the highest ethical and legal standards, and that this team promoted a strong performance-based culture centered on integrity, collaboration, innovation, diversity, and corporate responsibility.
The lawsuit further alleges that on September 12, 2023, Orthofix announced the immediate appointment of an interim CEO, interim CFO, and interim CLO. This change followed the “unanimous decision by the Board’s independent directors to terminate for cause Keith Valentine, John Bostjancic, and Patrick Keran from their respective positions.” The complaint asserts that the Board found these executives had engaged in repeated inappropriate and offensive conduct that breached multiple code of conduct requirements and was inconsistent with the company’s values and culture. As a result of this announcement, Orthofix’s stock price reportedly fell by more than 30%, according to the complaint.
